How long the effects of TMS last — what researchers call its "durability," meaning how long the benefits of TMS persist after treatment ends — isn't a single statistic. It depends significantly on which type of TMS you received, whether you reached full symptom relief, and a handful of individual factors specific to your depression history.
Many patients stay well for a year or more after a single course of TMS treatment, but the path to that outcome — and how to protect it — looks different depending on those variables. Understanding them means you can go into treatment and the months after it with a clearer picture of what to expect.
In this article, we'll cover:
The most comprehensive picture of how long the effects of TMS last comes from a 2019 meta-analysis that pooled data from 19 studies and over 700 patients. Among people who responded to their initial treatment, roughly 67% maintained their improvement at three months, 53% at six months, and 46% at twelve months — without any structured follow-up or booster sessions in place.
The majority of patients experience lasting benefit for at least several months after completing a full course of treatment. By the one-year mark, about half have experienced some degree of symptom return — though for many, that's a gradual drift rather than a sudden relapse, and it typically responds well to brief follow-up treatment.
The largest real-world study tracked 257 patients across 42 U.S. clinics for a full year after their initial treatment. Among those who achieved full remission — meaning their symptoms resolved, not just improved — 71% did not fully relapse during the twelve-month follow-up period. Among those who did experience symptom return, 84% regained their improvement after receiving booster sessions.
Two things stand out from that data:
TMS works in a way that produces real, lasting change in how the brain functions — for most patients, well beyond the end of treatment.
The brain doesn't stop responding to TMS the way it can stop responding to antidepressant medications over time. Patients who respond to an initial course tend to respond again if they need additional retreatments.
Sources: Senova et al. 2019 — rTMS remission rate and 12-month durability (19 studies, 700+ patients). Dunner et al. 2014 — 12-month naturalistic follow-up, patients achieving full remission. Janicak et al. 2010 — booster session response. Cole et al. 2022 / Geoly et al. 2025 — SAINT-based remission rate. Stimpson et al. 2025 — 12-month remission with proactive booster follow-up.
The middle bar is lower for accelerated TMS than standard rTMS — but that's not the full picture. Accelerated TMS starts from a 79% remission rate vs. 30% for standard rTMS, so even with more natural drift over time, more patients are still well at 12 months in absolute terms. With proactive booster sessions added, 86% maintain remission vs. 71% for standard rTMS.
TMS treatment is not one-size-fits-all. The three main types differ in how sessions are structured, how much total stimulation is delivered, and what the long-term outcome research shows. Here's what the evidence tells us for each.
Standard rTMS — the most widely available type — has the longest track record and the most follow-up research. A standard course involves daily sessions five days a week over four to six weeks, with 20 to 30 sessions total, each lasting around 37 minutes. The magnetic coil is placed against the scalp, delivering pulses that stimulate nerve cells in the prefrontal cortex, the region of the brain most closely linked to mood regulation.
At the end of a standard rTMS course, roughly 50% of patients see meaningful improvement and about 30% reach full remission — meaning their symptoms resolve substantially. The durability data above is drawn primarily from rTMS studies, making it the reference point against which the newer types of TMS are measured.
One limitation worth naming: standard rTMS uses body landmarks to estimate where to place the coil, with error margins that can reach up to 2cm. That means the specific area of the brain being targeted may shift from session to session, or may not be the most relevant site for a given patient in the first place. Imprecise targeting is one of the factors researchers believe contributes to only experiencing partial improvement and shorter-lasting results.
Deep TMS uses a different coil design that allows the magnetic field to reach deeper into the brain than standard rTMS. A full course runs 12 weeks — a first phase of 20 treatment sessions over four weeks, followed by a continuation phase of two sessions per week for eight more weeks.
That second phase is a deliberate feature for sustaining results. It functions as a built-in maintenance treatment, reinforcing the brain changes from the first phase while those changes are still consolidating. Long-term follow-up data for dTMS is still being collected, but the extended format appears to support more sustained outcomes for patients who complete both phases.
Accelerated TMS compresses what would otherwise be weeks of treatment into five days by delivering multiple sessions per day. It uses a magnetic pulse pattern called intermittent theta burst stimulation (iTBS) — a faster delivery method, FDA-approved, that mimics the brain's own natural rhythms and takes about 10 minutes per session rather than 37.
The most studied version, based on Stanford's SAINT™ protocol, delivers 10 sessions per day for five consecutive days — 50 total sessions equivalent in overall stimulation to a standard rTMS course. For a detailed overview of how this works, see our accelerated TMS guide.
The effectiveness data from the SAINT clinical trial is striking: approximately 79% of patients with treatment-resistant depression — meaning depression that hadn't responded to multiple prior treatments — reached full remission immediately after treatment.
On how long those results last: one tracking study found that 70% of patients achieved remission in the week following treatment, with 33% remaining in full remission at twelve weeks without any further treatment. The average duration of remission was approximately eleven weeks, and the average duration of meaningful improvement was about fifteen weeks. That staying power is comparable to both electroconvulsive therapy (ECT) and standard rTMS — accelerated TMS doesn't trade speed for lasting results.
Where the picture gets even more encouraging is with proactive follow-up. When patients were monitored remotely and received brief booster sessions only when early warning signs appeared, 86% maintained remission across a full twelve months — and most retreatment courses required just one to two days rather than a full five-day protocol.
In TMS research — and in your treatment — "response" and "remission" mean different things, and the distinction is one of the strongest predictors of how long results will last.
Response means a meaningful reduction in symptoms of depression, typically defined as a 50% or greater improvement on a standardized depression scale. You feel noticeably better, but some symptoms remain. Remission means reaching the point of full or near-full resolution — your depression is no longer significantly affecting your daily life.
Both are real outcomes. But they don't hold up equally over time. Research shows that patients who achieve full remission consistently maintain results longer than those who see partial improvement. The likely reason comes down to how the brain changes: remission appears to reflect a more complete reorganization of activity in the prefrontal cortex, rather than a partial shift that leaves the brain more vulnerable to reverting.
When some symptoms remain at the end of treatment, the brain hasn't fully consolidated the changes, and the path back to a symptomatic state is shorter. This is one reason why the quality of the initial treatment matters so much. A treatment plan that achieves deeper remission up front — through more precise targeting, adequate total stimulation, or therapy added alongside TMS — sets a more stable foundation than one that produces partial improvement.
For patients who saw meaningful improvement from TMS but didn't reach full remission: that doesn't mean the treatment failed, or that lasting relief isn't achievable. It often means that another course of TMS with better targeting, additional maintenance sessions, or therapy alongside it is what gets you there.
Beyond the type of TMS you received, several individual factors shape how long results hold.
Patients with a shorter history of depression and fewer prior episodes tend to see more durable results than those with long-standing, recurring illness. Research identifies incomplete remission after the initial course, a longer duration of depressive illness, and multiple prior medication failures as among the strongest predictors of needing ongoing maintenance sessions.
This doesn't mean TMS won't hold for patients with chronic or long-running depression — it means that having a proactive plan for monitoring and early retreatment becomes more important.
Patients who have tried and failed multiple antidepressants before TMS — the classic treatment-resistant depression profile — show more variable long-term outcomes than those for whom TMS was an earlier-line treatment. This is a reason for careful maintenance planning, not a reason to expect poor durability.
For context on where TMS fits relative to medication options, see our article on what to do when antidepressant medications don't work.
Conditions like post-traumatic stress disorder (PTSD), anxiety disorders, and bipolar depression can complicate the long-term picture. Patients dealing with more than one condition may achieve meaningful relief from TMS but often benefit from a more integrated treatment plan — combining TMS with ongoing talk therapy and, where appropriate, medication management.
Younger patients tend to respond faster and more fully to TMS, likely because younger brains are more plastic — meaning they adapt and reorganize more readily. Deeper remission up front tends to last longer, so that plasticity advantage extends to durability as well.
The strongest long-term outcomes in the research consistently come from combining TMS with antidepressant medications rather than using TMS alone. One randomized controlled trial found that monthly clustered TMS combined with antidepressants produced a relapse rate of just 15.9% over twelve months, compared to 44.4% for medication alone.
Whether to continue, adjust, or taper medication after TMS is a conversation to have with your healthcare provider — but the evidence doesn't support the idea that TMS replaces medication for everyone.
Standard rTMS uses body landmarks to estimate coil placement, with margins of error that can reach up to 2cm. fMRI-guided treatment — which uses a brain scan to map each patient's individual brain activity before the first session — identifies the exact target site and hits it within 1 to 2mm.
Early evidence suggests that this level of precision supports more durable outcomes, because consistently stimulating the right specific area produces more complete and stable changes in brain function. Larger long-term studies are still needed to fully confirm this, but the reasoning is solid and consistent with what we see clinically.
Standard rTMS produces full remission in roughly 30% of patients. The gap between that and what's possible comes down to two compounding problems:
Coil placement that may miss the most relevant target site in the brain.
A treatment format spread across four to six weeks, which many patients struggle to complete while managing work and daily life.
Both matter for how long results last. Stimulation that isn't reliably reaching the right site is less likely to produce the kind of stable, complete brain change that holds up over time. And treatment that patients don't finish doesn't produce remission at all.
Cognitive FX's accelerated fMRI-guided TMS — completed in a single week — addresses both. Before any stimulation begins, a functional MRI (fMRI) scan maps each patient's individual brain activity to locate the precise target site in the prefrontal cortex — the DLPFC, the region most involved in mood regulation — to within 1 to 2mm accuracy. FDA-approved neuronavigation then ensures that the same site is hit consistently across every session throughout the five-day course.
The full treatment delivers 50 sessions equivalent in total stimulation to the SAINT protocol, completed in one week rather than six. Cognitive behavioral therapy is built into the treatment week alongside TMS — supporting the depth of remission that predicts longer-lasting outcomes, and adding the roughly 19% remission boost that combined TMS and CBT produces over TMS alone.
On cost: Cognitive FX's treatment runs $7,000 to $12,000, compared to $30,000 or more for the licensed Magnus SAINT™ product. Standard rTMS is covered by most major insurers for qualifying patients; the accelerated protocol is currently self-pay.
For patients who do experience some symptom return, research shows that 9 out of 10 patients who relapsed after a first SAINT-based course achieved remission again with a second course — confirming that the brain's responsiveness to TMS is preserved across multiple rounds of treatment, and that a return of symptoms isn't the end of the road.
If you've been through multiple antidepressants without adequate relief, or are trying to understand whether TMS results are likely to hold for your specific situation, you can take our short quiz to see whether you're a likely candidate — or call 385-334-6093 to speak with someone directly.
What you do in the months after treatment interacts directly with whether those brain changes consolidate or gradually erode. Beyond working with mental health professionals on your ongoing care, several everyday habits make a real difference.
Research shows that cognitive behavioral therapy (CBT) combined with TMS improves the rate of meaningful improvement by approximately 8% and the rate of full remission by 19%, compared to TMS alone. Talk therapy — whether CBT or another evidence-based approach — helps build the thinking patterns and daily habits that reinforce what TMS does in the brain. Patients who stay in therapy after TMS tend to sustain the benefits longer than those who treat the end of TMS sessions as the end of active care.
The brain locks in the changes made during TMS while you sleep. Sleep disruption is both an early sign of depression returning and something that can speed up relapse. Consistent sleep — seven to nine hours on a regular schedule — is one of the most effective things you can do to extend how long TMS results hold. If sleep has been an ongoing struggle alongside depression, our article on fast-acting depression treatment options covers how sleep and mood interact.
Moderate aerobic exercise activates the same brain pathways that TMS engages — specifically the release of BDNF, a protein that supports brain cell health and adaptability. Thirty minutes most days isn't a substitute for treatment, but it meaningfully supports the brain environment in which TMS results are maintained.
Alcohol is a depressant that undermines both sleep quality and the brain's ability to regulate mood, interfering with the very neurological changes that TMS depends on to last.
Depression doesn't typically come back overnight — it develops gradually, often over weeks. Research on SAINT-based follow-up found that catching early warning signs and intervening with brief booster sessions before symptoms fully return produces dramatically better outcomes than waiting for a complete relapse. Patients who track their mood and stay in regular contact with their treatment team are far better positioned to do this.
If you find yourself wondering whether what you're experiencing signals a return of depression, our article on why depression won't go away covers what patterns to watch for.
Senova S, Cotovio G, Pascual-Leone A, et al. Durability of antidepressant response to repetitive transcranial magnetic stimulation: systematic review and meta-analysis. Brain Stimulation. 2019;12(1):119–128. doi:10.1016/j.brs.2018.10.002
Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry. 2014;75(12):1394–1401. doi:10.4088/JCP.13m08977
Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation. 2010;3(4):187–199. doi:10.1016/j.brs.2010.07.003
Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. American Journal of Psychiatry. 2022;179(2):132–141. doi:10.1176/appi.ajp.2021.20101429
Geoly A, Bentzley BS, Williams NR, et al. Durability of clinical benefit with Stanford Neuromodulation Therapy (SNT) in treatment-resistant depression. Brain Stimulation. 2025;18(3). doi:10.1016/j.brs.2025.03.006
Stimpson KH, Bentzley BS, Gerstle M, et al. Personalized continuation therapy with SAINT for maintaining remission in treatment-resistant depression. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation. 2025;6:100203. doi:10.1016/j.tms.2025.100203
d'Andrea G, Quaranta G, Simonetti A, et al. Investigating the role of maintenance TMS protocols for major depression: systematic review and future perspectives for personalized interventions. Journal of Personalized Medicine. 2023;13(4):697. doi:10.3390/jpm13040697
Pallanti S, Bernardi S, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? Neuroscience. 2010;167(2):323–328. doi:10.1017/S1092852900020034
Brakemeier EL, Wilbertz G, Rodax S, et al. Positive predictors for antidepressive response to prefrontal repetitive transcranial magnetic stimulation (rTMS). Journal of Psychiatric Research. 2008;42(3):170–177. doi:10.1016/j.jpsychires.2007.07.013
Wang YM, Li YY, Zhu XL, et al. Clustered repetitive transcranial magnetic stimulation for the prevention of depressive relapse/recurrence: a randomized controlled trial. Translational Psychiatry. 2017;7:e1292. doi:10.1038/tp.2017.274
Carpenter LL, Aaronson S, Clarke GN, et al. Consensus review and considerations on TMS to treat depression: a comprehensive update. Clinical Neurophysiology. 2024;168:25–59. doi:10.1016/j.clinph.2024.09.013
Geoly A, Azeez A, Stimpson KH, et al. Sustained efficacy of Stanford Neuromodulation Therapy (SNT) in open-label repeated treatment. American Journal of Psychiatry. 2024;181(1):65–72. doi:10.1176/appi.ajp.20230113
Dr. Mark D. Allen holds a Ph.D. in Cognitive Science from Johns Hopkins University and received post-doctoral training in Cognitive Neuroscience and Functional Neuroimaging at the University of Washington. As a co-founder of Cognitive Fx, he played a pivotal role in establishing the unique and exceptional treatment approach. Dr. Allen is renowned for his pioneering work in adapting fMRI for clinical use. His contributions encompass neuroimaging biomarkers development for post-concussion diagnosis and innovative research into the pathophysiology of chronic post-concussion symptoms. He's conducted over 10,000 individualized fMRI patient assessments and crafted a high-intensity interval training program for neuronal and cerebrovascular recovery. Dr. Allen has also co-engineered a machine learning-based neuroanatomical discovery tool and advanced fMRI analysis techniques, ensuring more reliable analysis for concussion patients.
You finished your TMS treatment. Your mood lifted, your energy returned, and for the first time in a long time, you felt like yourself again. But now a nagging question keeps surfacing: Will this...
With the original form of TMS therapy for major depressive disorder—known as repetitive transcranial magnetic stimulation (rTMS)—some patients begin noticing improvements within the first week of...
The stakes of finding the right TMS provider can feel understandably high. After all, patients suffering from mental health conditions such as major depressive disorder (MDD) or obsessive-compulsive...
For many people living with major depression, antidepressant medications either don’t work or only get them part of the way to recovery. Symptoms may ease for a while, but then return, or never fully...
If you’re wondering what to do when transcranial magnetic stimulation (TMS) doesn’t work, you might be:
"Did I lock the door? I'm sure I did. But what if I didn't? I should go back and check. I already checked twice, but maybe I didn't do it right. What if someone breaks in? What if something terrible...
